Expansion of available prequalified MPA API

Jan 10, 2017 | WHO PQ

On 22 December 2016, the WHO Prequalification Team prequalified the generic medroxyprogesterone acetate (MPA) active pharmaceutical ingredient (API), manufactured by Taizhou Taifa Pharmaceutical Co Ltd. in China.

This is only the 2nd MPA API to be prequalified by the WHO, thereby expanding the available options for manufacturers seeking to use quality assured materials for their products. Contraceptives containing MPA include the 3-monthly injectable depot medroxyprogesterone acetate (DMPA) and the monthly injectable contraceptive Cyclofem (MPA + estradiol cypionate).